The Hague, Netherlands

Miriam Verena Bujny

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 2.4

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019-2020

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Miriam Verena Bujny

Introduction

Miriam Verena Bujny is a prominent inventor based in The Hague, Netherlands. She has made significant contributions to the field of medical research, particularly in the development of human antibodies for influenza treatment. With a total of 2 patents, her work is paving the way for advancements in vaccine development and infectious disease management.

Latest Patents

Miriam's latest patents include groundbreaking inventions related to human neutralizing antibodies that bind to influenza neuraminidase. The first patent focuses on antibodies capable of specifically binding to and neutralizing at least one influenza B virus strain from the B/Victoria lineage and/or the B/Yamagata lineage. This invention also covers the use of these antibodies in the diagnosis, prophylaxis, and treatment of influenza infections. The second patent addresses human antibodies that neutralize at least one influenza A virus strain comprising neuraminidase of the N1 subtype, with capabilities extending to strains with the N2 subtype as well. This invention similarly relates to the use of these antibodies in combating influenza infections.

Career Highlights

Miriam is currently employed at Janssen Vaccines & Prevention B.V., where she continues her research and development efforts. Her work is instrumental in advancing the understanding and treatment of influenza, contributing to public health initiatives.

Collaborations

Miriam collaborates with notable colleagues, including Remko Van Der Vlugt and Donata De Marco. These partnerships enhance her research capabilities and foster innovation in the field.

Conclusion

Miriam Verena Bujny's contributions to the field of medical research through her patents on human neutralizing antibodies are significant. Her work at Janssen Vaccines & Prevention B.V. exemplifies the impact of innovative research on public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…